Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 2:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–33 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Multiple Sclerosis
Interventions
ponesimod, teriflunomide
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
10
States / cities
Carlsbad, California • Pomona, California • Denver, Colorado + 7 more
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
19
States / cities
Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 15 more
Conditions
Multiple Sclerosis
Interventions
Frexalimab, Teriflunomide, Placebo infusion, Placebo tablet, MRI contrast-enhancing agents, Cholestyramine, Activated charcoal
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
99
States / cities
Birmingham, Alabama • Cullman, Alabama • Homewood, Alabama + 84 more
Conditions
Relapsing Multiple Sclerosis
Interventions
Teriflunomide, Evobrutinib
Drug
Lead sponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
51
States / cities
Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 44 more
Conditions
Multiple Sclerosis
Interventions
Teriflunomide (HMR1726)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
4
States / cities
Maitland, Florida • Fort Wayne, Indiana • Detroit, Michigan + 1 more
Conditions
Relapsing Multiple Sclerosis
Interventions
Fenebrutinib, Teriflunomide, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
32
States / cities
Birmingham, Alabama • Homewood, Alabama • Phoenix, Arizona + 28 more
Conditions
HAM/TSP
Interventions
Teriflunomide
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Multiple Sclerosis Relapse
Interventions
Teriflunomide, Placebo (for teriflunomide), Interferon-beta (IFN-beta)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Cullman, Alabama • Cordova, Alaska • Phoenix, Arizona + 26 more
Conditions
Multiple Sclerosis
Interventions
Placebo, Teriflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • Loma Linda, California + 35 more